Importantly, we discovered that silencing TUG1 expression could improve the effector T cell killing capacity by suppressing the JAK2/STAT3/PD-L1 signaling pathway in vitro, which suggests that LncTUG1 may be developed to improve PD-1/PD-L1-based therapeutics for HCC. The gene discussed is JAK2; the disease is hepatocellular carcinoma.